newsfilter
← Latest News
ACCESS Newswire·

MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing on Early Clinical Efficacy Demonstration for Neuropathic Pain in 2025

MIAMI, FL / ACCESSWIRE / September 18, 2024 / MIRA Pharmaceuticals, Inc. , a preclinical-stage pharmaceutical company focused on developing innovative therapies for neurologic and neuropsychiatric disorders,